Glonghui May 27 丨 Minotis (603538)(603538JungleJackpotJourney.SH) AnnouncementJungleJackpotJourneyRecently, the company's holding subsidiary Zhejiang Minovanovic Propifenolate Fumarate and Tenofovir API passed the technical review of the Center for Drug Evaluation of the State Food and Drug Administration (hereinafter referred to as "CDE"), and the CDE API, pharmaceutical excipients and Pharmaceutical packaging materials registration information disclosure platform displays that the registration number has changed to "A" status.
The name of the drug substance is tenofovir propionate and is suitable for the treatment of chronic hepatitis B in adults and adolescents (age 12 years and above, weighing at least 35kg).
Zhejiang MeinuohuaJungleJackpotJourneyThe tenofovir propionate-tenofovir crude drug substance passed the CDE technical review, which proved that the crude drug substance has met the relevant national technical standards for drug review and can be sold to the domestic market. This will further enrich the subsidiary's product line and help expand the company's business field will help further expand the company's integrated production scope of API preparations and enhance the company's integrated production advantages.